bluebird bio (BLUE) to Release Earnings on Tuesday

bluebird bio (BLUE) to Release Earnings on Tuesday

bluebird bio (NASDAQ:BLUE) is scheduled to post its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect bluebird bio to post earnings of ($1.68) per share for the quarter.

bluebird bio (BLUE) opened at $213.35 on Monday. The firm has a market capitalization of $10,460.00, a P/E ratio of -30.44 and a beta of 2.07. bluebird bio has a 12-month low of $73.95 and a 12-month high of $222.03.

A number of equities analysts have weighed in on the company. Canaccord Genuity reissued a “buy” rating and set a $250.00 price target on shares of bluebird bio in a research report on Thursday, February 1st. Wells Fargo & Co reissued an “outperform” rating and set a $242.00 price target (up previously from $190.00) on shares of bluebird bio in a research report on Tuesday, December 12th. CIBC assumed coverage on bluebird bio in a research report on Thursday, December 21st. They set a “market perform” rating on the stock. Barclays boosted their price target on bluebird bio from $151.00 to $162.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. Finally, Jefferies Group reissued a “hold” rating and set a $130.00 price target on shares of bluebird bio in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $161.45.

In related news, COO Susanna Gatti High sold 1,282 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the sale, the chief operating officer now owns 13,718 shares of the company’s stock, valued at $2,361,553.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Vachon sold 7,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $216.64, for a total value of $1,516,480.00. Following the sale, the director now directly owns 8,000 shares in the company, valued at approximately $1,733,120. The disclosure for this sale can be found here. Insiders sold 200,280 shares of company stock worth $37,818,846 in the last ninety days. 3.90% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “bluebird bio (BLUE) to Release Earnings on Tuesday” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/19/bluebird-bio-blue-to-release-earnings-on-tuesday.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

bluebird bio (NASDAQ:BLUE) is set to issue its quarterly earnings data after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($1.68) per share for the quarter.

Shares of bluebird bio (NASDAQ:BLUE) opened at $213.35 on Monday. bluebird bio has a 12 month low of $73.95 and a 12 month high of $222.03. The firm has a market capitalization of $10,460.00, a price-to-earnings ratio of -30.44 and a beta of 2.07.

BLUE has been the subject of several recent analyst reports. BMO Capital Markets upped their target price on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. Cantor Fitzgerald restated a “sell” rating and set a $58.00 target price (up from $39.00) on shares of bluebird bio in a research note on Wednesday, November 1st. Leerink Swann restated an “outperform” rating and set a $162.00 target price (up from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. BTIG Research upgraded bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price target for the company in a research note on Thursday, November 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $174.00 price target (up from $135.00) on shares of bluebird bio in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $161.45.

In related news, COO Susanna Gatti High sold 1,282 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the transaction, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Philip D. Gregory sold 2,250 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.54, for a total value of $388,215.00. Following the transaction, the insider now directly owns 28,734 shares of the company’s stock, valued at $4,957,764.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 200,280 shares of company stock valued at $37,818,846. 3.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/19/bluebird-bio-blue-to-release-earnings-on-tuesday.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply